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Background: A large number of longitudinal studies of population-based ageing cohorts are in progress internationally,
but the insights from these studies into the risk and protective factors for cognitive ageing and conditions like mild
cognitive impairment and dementia have been inconsistent. Some of the problems confounding this research can be
reduced by harmonising and pooling data across studies. COSMIC (Cohort Studies of Memory in an International
Consortium) aims to harmonise data from international cohort studies of cognitive ageing, in order to better understand
the determinants of cognitive ageing and neurocognitive disorders.
Methods/Design: Longitudinal studies of cognitive ageing and dementia with at least 500 individuals aged 60 years or
over are eligible and invited to be members of COSMIC. There are currently 17 member studies, from regions that
include Asia, Australia, Europe, and North America. A Research Steering Committee has been established, two meetings
of study leaders held, and a website developed. The initial attempts at harmonising key variables like
neuropsychological test scores are in progress.
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Discussion: The challenges of international consortia like COSMIC include efficient communication among members,
extended use of resources, and data harmonisation. Successful harmonisation will facilitate projects investigating rates
of cognitive decline, risk and protective factors for mild cognitive impairment, and biomarkers of mild cognitive
impairment and dementia. Extended implications of COSMIC could include standardised ways of collecting and
reporting data, and a rich cognitive ageing database being made available to other researchers. COSMIC could
potentially transform our understanding of the epidemiology of cognitive ageing, and have a
world-wide impact on promoting successful ageing.
Keywords: Cohort studies, Cognitive ageing, Data harmonisation, Dementia, International consortium, Mild cognitive
impairmentBackground
The ageing of our populations, with the increasing preva-
lence of physical and cognitive disorders associated with
age, poses a major burden on society [1]. Making an im-
pact on this disability burden requires an understanding
of the risk and protective factors for age-related cog-
nitive decline, frailty and chronic disease. The optimal
approach to study this involves the longitudinal examin-
ation of population-based ageing cohorts. There are many
such studies currently ongoing internationally, but there is
considerable inconsistency in the results produced [2] and
further systematic examination of the existing evidence is
required to determine findings which are robust.
Some of the variation in prevalence rates and risk fac-
tors identified across studies may be associated with re-
gional and/or ethnic differences. For example, rates of
non-amnestic mild cognitive impairment (MCI) are re-
ported to be higher in blacks than whites from a similar
geographical location, even when controlling for sex and
education [3]. However, a significant proportion of the
variance between studies is likely attributable to differ-
ences in methodology, including differences in the assess-
ment tools and performance criteria used for diagnosing
cognitive disorders. Indeed, small but theoretically valid
changes to how objective cognitive impairment was oper-
ationally defined led to greatly elevated prevalence rates,
from 4% to 70% [4]. Similarly, using different criteria for
the diagnosis of dementia can result in vastly different
prevalence figures [5].
There are a number of approaches for overcoming
methodological differences and other sources of hetero-
geneity so that studies can be more accurately compared
and true differences identified. These include the use of
standardised protocols, meta-analysis, and harmonisa-
tion of data [6]. The use of standardised or even similar
protocols is a rare feature of existing collaborations (the
10/66 Dementia Research Group is one exception [7]),
and meta-analysis is limited to published results. In con-
trast, data harmonisation offers the potential to explore
both existing and novel research questions by a cost-
effective use of previously-collected data.Harmonising data across studies to create a single, large
database helps to minimise the influence of both study-
level (e.g., methodology) and individual level (e.g., demo-
graphic) factors, while also enabling these to be explored
as potential contributors to differences in results [8,9].
Other advantages include increased statistical power
for detecting effects, and the inherent replication and
enhanced generalisability associated with using heteroge-
neous samples and methodologies [8].
COSMIC (Cohort Studies of Memory in an International
Consortium) is a recently established endeavour that aims
to bring together cohort studies of cognitive ageing inter-
nationally in order to facilitate a better understanding of
the determinants of cognitive ageing and neurocognitive
disorders. The two main objectives of this project are to:
1. Harmonise shared, non-identifiable data from cohort
studies that longitudinally examine change in
cognitive function and the development of dementia
in older individuals (60+ years).
2. Perform joint or mega-analyses using combined,
harmonised data sets that yield collated results with
enhanced statistical power, in addition to comparisons
across geographical regions, ethnicities and
sociocultural groups.
Other collaborations bringing together cohort studies of
ageing include the genetics-focused CHARGE (Cohorts
for Heart and Aging Research in Genomic Epidemiology)
[10] and ENIGMA (Enhancing NeuroImaging Genetics
through Meta-Analysis) [11]. Consortia with a particu-
lar interest in cognitive ageing include the UK-based
HALCyon (Healthy Ageing across the Life Course) [12],
the primarily Europe-based CHANCES (Consortium on
Health and Ageing: Network of Cohorts in Europe and
the United States) [13], the Australian-based DYNOPTA
(Dynamic Analyses to Optimise Ageing) [14], and the
IALSA (Integrative Analysis of Longitudinal Studies on
Aging) network [15], which has member studies from
Europe, North America and Australia. None of these con-
sortia have any studies from Asia, where the current and
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to be greater than that of Europe and the Americas com-
bined [1]. COSMIC hopes to distinguish itself by being a
truly international effort comprising studies with a clinical
and biomedical focus from Asia, Europe, the Americas,
and Oceania. COSMIC was established in 2012, with pro-
gress reported in 2013 [16].
Methods/design
Membership
Studies are eligible to participate in COSMIC if they
meet the following membership criteria:
1. Are epidemiological, and therefore population-based.
2. Have a minimum sample size of 500.
3. Examine individuals aged 60 years and over.
4. Are longitudinal, with a minimum of two
assessments.
5. Include assessment of cognitive function as an
important, if not central, objective.
6. The outcome measures include dementia and/or
cognitive impairment and/or cognitive decline.
Official enrolment in COSMIC involves a lead investi-
gator having signed a memorandum of understanding
that entails a willingness to share non-identifiable raw
and/or processed data for joint or mega-analyses. Studies
that, for institutional or other reasons, are unable to
provide raw and/or processed data may participate in
COSMIC as provisional members, if willing to provide
results of in-house analyses conducted using COSMIC
protocols. At the time of writing there are 14 officially
enrolled and 3 provisional members of COSMIC. These
studies, and their key demographic characteristics, are
shown in Table 1. It is intended that the overall sample
size and range of geographical regions and ethnicities rep-
resented be extended even further, and thus we ask that
any study meeting the eligibility criteria consider contact-
ing us to become a member of COSMIC. Studies from
Africa, South America and Eastern Europe are particu-
larly encouraged to join.
Organisation
COSMIC has a Research Steering Committee comprising
one representative from each participating study, generally
the lead investigator or a delegate. The primary functions
of the Research Steering Committee are:
1. To develop guidelines for the inclusion and
exclusion of studies.
2. To provide rules of participation and guidelines for the
roles and responsibilities of the participating studies.
3. To approve Workgroups.
4. To select topics of interest.5. To provide overall analytic strategies.
6. To develop rules for publication, including
authorship.
7. To develop rules for the protection of intellectual
property, when relevant.
8. To seek funds to support COSMIC.
Meetings
An initial meeting of many (now member) study leaders
on July 16, 2012 in Vancouver supported the official estab-
lishment of COSMIC. Potential projects, both initial and
more long-term, and the steps needed to progress these
were among the topics discussed. A subsequent meeting
comprising many of the Research Steering Committee
members was held on July 15, 2013 in Boston.
Website
A website has been established that contains a de-
scription of COSMIC and summaries of the member
studies (http://www.cheba.unsw.edu.au/group/cosmic).
This website is intended to serve as an avenue for
presenting and preserving COSMIC project protocols
and results, and will potentially house data restricted by
password to COSMIC members. The Sydney team are
currently responsible for the development and mainten-
ance of the COSMIC website.
Ethics
The overall COSMIC project has been approved by the
Human Research Ethics Committee of the University of
New South Wales, Sydney. Member studies are respon-
sible for obtaining approval (if considered necessary)
from their local institutional review board for the sharing
of data. However, de-identified data are not considered
Protected Health information by the National Institute of
Health of the USA. A protocol for the de-identification of
data has been developed.
Discussion
Challenges
General challenges facing large, international consortia
have been previously described (e.g., by CHARGE [10]).
These include a potential need for additional funding to
prolong the use of study data beyond initial anticipa-
tions, and timely and effective communication among
members across different countries.
More specific to COSMIC are challenges associated with
harmonisation, many of which have also been previously
described [9,35]. The major challenge of harmonisation
stems from differences between studies in the measure-
ment instruments used and/or differences in how ques-
tions from similar instruments are worded and responses
provided and categorised, including the effect of language
and culture. Attempts to maximise the number of studies
Table 1 COSMIC member studies
Study Country Sample size Age range Males (%) Main races/ethnicities Start and
end date
Key reference(s)
Canadian Study of Health and Aging (CSHA) Canada 10263 65-102 43 Caucasian 1991-2002 CSHA Working Group (1994) [17]
Chinese Longitudinal Ageing Study (CLAS)* China 3514 60+ 44 Chinese 2010- Xiao et al. (2013) [18]
Cognitive Function and Ageing Studies (CFAS)† UK 13004 65+ 40 Caucasian 1991- Brayne et al. (2006) [19]
Einstein Aging Study (EAS)* USA 1956 66-104 39 Caucasian/African
American
1993- Katz et al. (2012) [3]
Etude Santé Psychologique Prévalence Risques et
Traitement (ESPRIT)*
France 2268 65+ 42 Not recorded 1999- Ritchie et al. (2010) [20]
Framingham Heart Study (FHS)† USA 15328‡ 5+ 50 Caucasian 1948- Dawber & Kannel (1958) [21];
Feinleib et al. (1975) [22];
Splansky et al. (2007) [23]
Hong Kong Memory and Ageing Prospective Study
(HK-MAPS)*
Hong Kong 787 60+ 46 Chinese 2005- Wong et al. (2013) [24]
Korean Longitudinal Study on Cognitive Aging and
Dementia (KLOSCAD)
South Korea 6479 60+ 44 Korean 2009- Kim et al. (2013) [25]
Mayo Clinic Study of Aging (MCSA)† USA 4000 50-89 50 Caucasian 2004- Roberts et al. (2008) [26]
Monongahela Valley Independent Elders Survey (MoVIES)* USA 1681 65+ 42 Caucasian 1987-2002 Ganguli et al. (2000) [27]
Personality and Total Health (PATH) Through Life Project* Australia 2551 60-64 52 Caucasian 2001- Anstey et al. (2012) [28]
Singapore Longitudinal Ageing Studies (SLAS) I and II* Singapore 5748 54-98 37 Chinese 2003- Feng et al. (2010, 2013) [29,30]
Sydney Memory and Ageing Study (Sydney MAS)* Australia 1037 70+ 45 Caucasian 2005- Sachdev et al. (2010) [31]
Tajiri Project Japan 1654 65+ 42 Japanese 1998-2005 Meguro et al. (2002) [32]
Washington Heights Inwood and Columbia Aging
Project (WHICAP)*
USA 4577 63-103 32 Hispanic/African
American/Caucasian
1989- Tang et al. (2001) [33]
ZARADEMP Project (ZARAgoza DEMentia DEPression Project)* Spain 4803 55+ 42 Caucasian 1994- Lobo et al. (2005) [34]
*Data for the first project have been made available.
†Provisional member.
‡Including 3 generations (Original cohort, Offspring, Grandchildren) and separate Omni cohort of 900 ethnic minority participants.
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formation from some studies be simplified (e.g., converted
from a continuous measure to a categorical scale). There is
a potential reduction in validity involved in simplifying
data, but there are mechanisms by which this can be tested
and/or quantified [9].
Meeting the objectives of COSMIC will require various
data types to be harmonised, but data relating to cognitive
outcomes such as impairment and decline are likely to be
the most challenging (i.e., more so than demographic and
health-related variables). COSMIC member studies have
operationally defined cognitive outcomes in vastly differ-
ent ways. For example, for the purposes of diagnosing
MCI, cognitive impairment has been variously defined
as abnormal scores on the memory items of two cogni-
tive status instruments (Mini-Mental State Examination
and Geriatric Mental State Schedule) in the Zaragoza
Dementia Depression Project [36], and as a score on any
measure from a comprehensive neuropsychological bat-
tery 1.5 or more standard deviations below published nor-
mative values in the Sydney Memory and Ageing Study
[31]. Different studies have used different neuropsycho-
logical test batteries, but even when similar cognitive tests
have been used it is often the case that different versions
have been used or the tests have been administered in a
non-standard way. An added complication is the need to
reconcile differences in the data while giving appropriate
consideration to relevant demographic effects, including
those associated with gender and education.
First project
The aim of the first COSMIC project is to compare the
baseline prevalence of MCI across the COSMIC member
cohorts and the different regions and ethnicities repre-
sented by these. The project is currently underway, and
is being coordinated by the Sydney team. A question-
naire was developed and promulgated, with the informa-
tion provided guiding a subsequent request for data
from the studies on:
1. Demographics.
2. Sample representativeness.
3. Neuropsychological test performance.
4. Functional test scores.
5. Memory/cognitive complain/concerns.
6. Criteria used for MCI.
The receipt of data was followed by communication
with data managers and/or study leaders to clarify the na-
ture of data (e.g., the particular neuropsychological test
used or manner of administration) and/or to ask that fur-
ther data be provided (e.g., the individual items from a
functional test scale in addition to a total score originally
provided). Data from 11 studies have been made availablefor this project (see Table 1), and there is a total sample
size of more than 23,000 non-demented individuals aged
60 and older.
Some demographic variables have been harmonised. All
studies provided age in years, and harmonising sex only
required some recoding to a common scale (female = 0;
male = 1). Education was less straightforward. A four-level
categorical scale of the highest level of education achieved
(Less than high school completion, High school comple-
tion, Technical or college diploma, University degree) was
chosen as the most appropriate common measure, and to
which various other categorical formats or years of formal
education were transformed (see Additional file 1 for the
protocol). Data were provided in the harmonised format
by the studies themselves, or later transformed from the
original variable by the project coordinators.
The next step will be to harmonise the data needed to
make classifications of MCI. The participating studies
have published widely varying rates of MCI, from as low
as 3.2% for the Monongahela Valley Independent Elders
Survey [37] to 34.8% for the Sydney Memory and Ageing
Study [31]. Differences between the studies in how MCI
diagnoses were made have undoubtedly contributed to
the varying prevalence rates [4], and minimising this re-
quires the harmonisation of data informing the four gen-
erally accepted criteria for MCI:
1. Absence of dementia.
2. No or minimal functional impairment.
3. Objective cognitive impairment.
4. Memory complaint or concern [38,39].
Future projects
A number of future projects utilising COSMIC data are
currently planned, and aim to make comparisons across
COSMIC cohorts, countries and ethnic groups of:
1. Risk and protective factors for MCI.
2. Rates of cognitive decline.
3. Biomarkers (e.g., blood, genetic and MRI-derived) of
MCI and dementia.
Many of the existing member studies have relevant
data to contribute to these projects. It is expected that
additional projects will address more refined and specific
topics addressing the overall objectives of COSMIC.
This could include identifying and comparing rates of
decline within particular cognitive domains, and estab-
lishing associations between untreated hypertension or
non-traditional risk factors and cognitive decline. Pro-
jects like these will be enabled and facilitated by growing
the COSMIC membership base to ensure that there are
sufficient relevant data on variables not collected by
all studies.
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The mechanisms for harmonising measures developed
by COSMIC could produce standardised ways of collect-
ing and reporting data that facilitate the comparability of
longitudinal studies of ageing. This includes previous or
existing studies, for which data could be reformatted
and further analysed. It may also guide the choice of
measures used or type of data collected by future stud-
ies, for which the capacity to directly compare results
with those of many other cohorts would greatly enhance
their interpretability and relevance.
There is also the potential for the COSMIC database
to be made available to non-consortium researchers via
the website, following consortia-based publications and
with the approval of the Research Steering Committee.
The scientific benefits of making large databases avail-
able to researchers worldwide are demonstrated by the
more than 250 publications reported to have arisen from
the sharing of ADNI (Alzheimer's Disease Neuroimaging
Initiative) data across the internet [40].
With these, and potentially further extended implica-
tions and uses of COSMIC data, member studies can be
confident that their data are being fully utilised and that
they are contributing to a truly global effort to under-
stand and combat the problems associated with cogni-
tive ageing, MCI and dementia.
Conclusion
The COSMIC project is a truly international effort to in-
form the epidemiology of cognitive disorders associated
with advanced age by identifying risk factors and bio-
markers that are common as well as unique. It has the po-
tential to transform our understanding of the epidemiology
of cognitive ageing and have a world-wide impact on pro-
moting successful ageing.
Additional file
Additional file 1: Protocol for harmonising education across
COSMIC member studies participating in the first project.
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